Effect of Korean Red Ginseng extracts on drug-drug interactions

• Published in: Journal of ginseng research 2018, 42(3), , pp.370-378
• Main Authors: Kim, Se-Jin, Choi, Seungmok, Kim, Minsoo, Park, Changmin, Kim, Gyu-Lee, Lee, Si-On, Kang, Wonku, Rhee, Dong-Kwon
• Format: Article
• Language: English
• Subjects: cytochrome P450; drug–drug interaction (DDI); Korean Red Ginseng (KRG); 기타의약학
• ISSN: 1226-8453; 2093-4947
• DOI: 10.1016/j.jgr.2017.08.008

Ginseng has been the subject of many experimental and clinical studies to uncover the diverse biological activities of its constituent compounds. It is a traditional medicine that has been used for its immunostimulatory, antithrombotic, antioxidative, anti-inflammatory, and anticancer effects. Ginseng may interact with concomitant medications and alter metabolism and/or drug transport, which may alter the known efficacy and safety of a drug; thus, the role of ginseng may be controversial when taken with other medications. We extensively assessed the effects of Korean Red Ginseng (KRG) in rats on the expression of enzymes responsible for drug metabolism [cytochrome p450 (CYP)] and transporters [multiple drug resistance (MDR) and organic anion transporter (OAT)] in vitro and on the pharmacokinetics of two probe drugs, midazolam and fexofenadine, after a 2-wk repeated administration of KRG at different doses. The results showed that 30 mg/kg KRG significantly increased the expression level of CYP3A11 protein in the liver and 100 mg/kg KRG increased both the mRNA and protein expression of OAT1 in the kidney. Additionally, KRG significantly increased the mRNA and protein expression of OAT1, OAT3, and MDR1 in the liver. Although there were no significant changes in the metabolism of midazolam to its major metabolite, 1′-hydroxymidazolam, KRG significantly decreased the systemic exposure of fexofenadine in a dose-dependent manner. Because KRG is used as a health supplement, there is a risk of KRG overdose; thus, a clinical trial of high doses would be useful. The use of KRG in combination with P-glycoprotein substrate drugs should also be carefully monitored.